The 2026 Nobel Prize in Physiology or Medicine honors discoveries that helped establish optogenetics. Ray Therapeutics is building on this scientific foundation to advance investigational optogenetic therapies designed to restore functional vision.
Restoring sight for those with blinding diseases.
We use the innovative technology of optogenetics to reprogram surviving neurons in the retina of the eye to sense light and send visual signals to the brain—restoring vision.
Paul Bresge
Chief Executive Officer
Chris Whitmore, CPA
Chief Financial Officer
Peter Francis, MD, PhD
Chief Medical & Scientific Officer
Jenny Holt
Chief Development Officer
Mike Murtagh
Chief Regulatory Officer
